Topical delivery of ocular therapeutics: Carrier systems and physical methods

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 4, 2014, Pages 507-530

  Souza, Joel G ^a   Dias, Karina ^a   Pereira, Tatiana Aparecida ^a   Bernardi, Daniela Spuri ^a   Lopez, Renata F V ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

contact lens; dendrimers; iontophoresis; nanoparticle; topical ocular delivery

Indexed keywords

CONTACT LENS; DENDRIMERS; IONTOPHORESIS; NANOPARTICLE; TOPICAL OCULAR DELIVERY;

ADMINISTRATION, TOPICAL; ANTERIOR CHAMBER; CONTACT LENSES; DENDRIMERS; DRUG DELIVERY SYSTEMS; EMULSIONS; EYE DISEASES; HUMANS; HYDROGELS; LIPIDS; LIPOSOMES; NANOPARTICLES;

EID: 84899090733     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12132     Document Type: Review

References (283)

1. Vandervoort J, Ludwig A,. Ocular drug delivery: nanomedicine applications. Nanomedicine 2007; 2: 11-21.
2. Gaudana R, etal. Ocular drug delivery. AAPS J 2010; 12: 348-360.
3. Hughes PM, etal. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev 2005; 57: 2010-2032.
4. Gaudana R, etal. Recent perspectives in ocular drug delivery. Pharm Res 2009; 26: 1197-1216.
5. Le-Bourlais CL, etal. Ophthalmic drug delivery systems recent advances. Prog Retin Eye Res 1998; 17: 33-58.
6. Duvvuri S, etal. Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther 2003; 3: 45-56.
7. Durajai C, etal. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res 2009; 26: 1236-1260.
8. Kim SW, etal. Hydrogel: swelling, drug loading and release. Pharm Res 1992; 9: 283-290.
9. Ausayakhun S, etal. Treatment of cytomegalovirus retinitis in AIDS patients with intravitreal ganciclovir. J Med Assoc Thai 2005; 88 (Suppl. 9): bS15-bS20.
10. Diebold I, Calone M,. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 2010; 29: 596-609.
11. Kompella UB, etal. Recent advances in ophthalmic drug delivery. Ther Deliv 2010; 1: 435-456.
12. Sultana Y, etal. Nanotechnology in ocular delivery: current and future directions. Drugs Today (Barc) 2011; 47: 441-455.
13. Kompella UB, etal. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res 2013; 36: 172-198.
14. Gan L, etal. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today 2013; 18: 290-297.
15. Cholkar K, etal. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther 2013; 29: 106-123.
16. Lawrence MJ, Rees GD,. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000; 45: 89-121.
17. Fanun M,. Microemulsions as delivery systems. Curr Opin Colloid Interface Sci 2012; 17: 306-313.
18. Gratieri T, etal. Cutaneous drug delivery using nano/Microsystems combined with physical methods for permeation enhancement. In:, Lopez RFV, etal., eds. Physical Methods to Increase Topical and Transdermal Drug Delivery. Kelara: Transworld Research Network, 2012: 161-191.
19. Araújo LM, etal. Development of microemulsions to topically deliver 5-aminolevulinic acid in photodynamic therapy. Eur J Pharm Biopharm 2010; 75: 48-55.
20. Vandamme THF,. Microemulsions as ocular drug delivery systems: recent developmentsand future challenges. Prog Retin Eye Res 2002; 21: 15-34.
21. Meng J, etal. Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur J Pharm Sci 2011; 44: 57-67.
22. Yin YM, etal. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Control Release 2009; 140: 86-94.
23. Jarvinen K, etal. Ocular absorption following topical delivery. Adv Drug Deliv Rev 1995; 16: 3-19.
24. Chiou GCY, Zheng YQ,. Permeation enhancement via the ocular route. In:, Hsieh D, ed. Drug Permeation Enhancement: Theory and Applications. New York: Marcel Dekker, 1994: 405-406.
25. Gasco MR, etal. Microemulsions as topical delivery vehicles: ocular administration of timolol. J Pharm Biomed Anal 1989; 7: 433-439.
26. Alany RG, etal. W/O microemulsions for ocular delivery: evaluation of ocular irritation and precorneal retention. J Control Release 2006; 11: 145-152.
27. Chan J, etal. Effect of water-in-oil microemulsions and lamellar liquid crystalline systems on the precorneal tear film of albino New Zealand rabbits. Clin Ophthalmol 2008; 2: 129-138.
28. Chan J, etal. Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. Int J Pharm 2007; 328: 65-71.
29. Gan L, etal. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results. Int J Pharm 2009; 365: 143-149.
30. Naveh N, etal. Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits. J Ocul Pharmacol 1994; 10: 509-520.
31. Garty N, Lusky M,. Pilocarpine in submicron emulsion formulation for treatment of ocular hypertension: a phase II clinical trial. Invest Ophthalmol Vis Sci 1994; 35: 2175-2179.
32. Beilin M, etal. Ocular retention time of submicron emulsion (SME) and the miotic response to pilocarpine delivered in SME. Invest Ophthalmol Vis Sci 1995; 36: S166.
33. Kesavan K, etal. Mucoadhesive chitosan-coated cationic microemulsion of dexamethasone for ocular delivery: in vitro and in vivo evaluation. Curr Eye Res 2012; 38: 342-352.
34. Hagigit T, etal. Ocular antisense oligonucleotide delivery by cationic nanoemulsion for improved treatment of ocular neovascularization: an in vivo study in rats and mice. J Control Release 2012; 160: 225-231.
35. Lallemand F, etal. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv 2012; 2012:604204: 1-16.
36. Hagigit T, etal. Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye. J Control Release 2010; 145: 297-305.
37. Hagigit T, etal. The influence of cationic lipid type on in-vitro release kinetic profiles of antisense oligonucleotide from cationic nanoemulsions. Eur J Pharm Biopharm 2008; 70: 248-259.
38. Yan W, etal. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol 2007; 44: 3672-3681.
39. Fujisawa T, etal. Liposomal diclofenac eye drop formulations targeting the retina: formulation stability improvement using surface modification of liposomes. Int J Pharm 2012; 436: 564-567.
40. Jiao J,. Polyoxyethylated nonionic surfactants and their application in topical ocular drug delivery. Adv Drug Deliv Rev 2008; 60: 1663-1673.
41. Tamilvanan S, Kumar BA,. Influence of acetazolamide loading on the (in vitro) performances of non-phospholipid-based cationic nanosized emulsion in comparison with phospholipid-based anionic and neutral-charged nanosized emulsions. Drug Dev Ind Pharm 2011; 37: 1003-1015.
42. Yamaguchi M, etal. Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid. Biol Pharm Bull 2009; 32: 1266-1271.
43. Gallarate M, etal. Development of O/W nanoemulsions for ophthalmic administration of timolol. Int J Pharm 2013; 440: 126-134.
44. Badawi AA, etal. Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res 2008; 31: 1040-1049.
45. Wei J, etal. Chitosan-coated ophthalmic submicro emulsion for pilocarpine nitrate. Acta Pharmacol Sin 2011; 46: 990-996. [In Chinese].
46. De la Fuente M, etal. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev 2010; 62: 100-117.
47. Abdelbary G,. Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes. Pharm Dev Technol 2011; 16: 44-56.
48. Jiang M, etal. Cationic core-shell liponanoparticle for ocular drug gene delivery. Biomaterials 2012; 33: 7621-7630.
49. Diebold Y, etal. Ocular drug delivery by liposome -chitosan nanoparticle complexes (LCS-NP). Biomaterials 2007; 28: 1553-1564.
50. Li N, etal. Low molecular weight chitosan-coated liposomes for ocular drug delivery: in vitro and in vivo studies. Drug Deliv 2012; 19: 28-35.
51. Zhang J, Wang S,. Topical use of coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. Int J Pharm 2009; 372: 66-75.
52. Luo Q, etal. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011; 403: 185-191.
53. Wadhwa S, etal. Chitosan and its role in ocular therapeutics. Mini Rev Med Chem 2009; 9: 1639-1647.
54. Gratieri T, etal. Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel. Eur J Pharm Biopharm 2011; 79: 320-327.
55. Cao Y, etal. Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery. J Control Release 2007; 120: 186-194.
56. Gratieri T, etal. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm 2010; 75: 186-193.
57. Gupta S, Vyas SP,. Carbopol/chitosan based pH triggered in situ gelling system for ocular delivery of timolol maleate. Sci Pharm 2010; 78: 959-976.
58. Bhatta RS, etal. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: in vitro and pharmacokinetics studies. Int J Pharm 2012; 432: 105-112.
59. Mahmoud AA, etal. Chitosan/sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int J Pharm 2011; 413: 229-236.
60. Nagarwal RC, etal. Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: characterization, in-vitro and in-vivo study. Chem Pharm Bull 2011; 59: 272-278.
61. Jain GK, etal. Microscopic and spectroscopic evaluation of novel PLGA-chitosan Nanoplexes as an ocular delivery system. Colloids Surf B Biointerfaces 2011; 82: 397-403.
62. Nagarwal RC, etal. Chitosan coated PLA nanoparticles for ophthalmic delivery: characterization, in-vitro and in-vivo study in rabbit eye. J Biomed Nanotechnol 2010; 6: 648-657.
63. Contreras-Ruiz L, etal. Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells. Mol Vis 2011; 17: 279-290.
64. Calvo P, etal. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J Pharm Pharmacol 1996; 48: 1147-1152.
65. De Campos AM, etal. The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci 2003; 20: 73-81.
66. Ludwing A,. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 2005; 57: 1595-1693.
67. Nagarwal RC, etal. Chitosan coated sodium alginate-chitosan nanoparticles loaded with 5-FU for ocular delivery: in vitro characterization and in vivo study in rabbit eye. Eur J Pharm Sci 2012; 47: 678-685.
68. Srividya B, etal. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release 2001; 73: 205-211.
69. Mandal S, etal. Formulation and evaluation of an in situ gel-forming ophthalmic formulation of moxifloxacin hydrochloride. Int J Pharm Investig 2012; 2: 78-82.
70. White CJ, etal. Extended release of high molecular weight hydroxypropyl methylcellulose from molecularly imprinted, extended wear silicone hydrogel contact lenses. Biomaterials 2011; 32: 5698-5705.
71. Elbaz E, etal. Positively charged submicron emulsions-a new type of colloidal drug carrier. Int J Pharm 1993; 96: R1-R6.
72. Muchtar S, Benita S,. Emulsions as drug carriers for ophthalmic use. Colloids Surf A 1994; 91: 181-190.
73. Calvo P, etal. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci 1996; 85: 530-536.
74. Teixeira H, etal. Submicron cationic emulsions as a new delivery system for oligonucleotides. Pharm Res 1999; 16: 30-36.
75. Hoeller S, etal. Lecithin based nanoemulsions: a comparative study of the influence of non-ionic surfactants and the cationic phytosphingosine on physicochemical behaviour and skin permeation. Int J Pharm 2009; 370: 181-186.
76. Attama AA, etal. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008; 355: 307-313.
77. Jain RL, Shastri JP,. Study of ocular drug delivery system using drug-loaded liposomes. Int J Pharm Investig 2011; 1: 35-41.
78. Gupta H, etal. Ion- and pH-activated novel in-situ gel system for sustained ocular drug delivery. J Drug Target 2010; 18: 499-505.
79. Vega E, etal. PLGA nanospheres for the ocular delivery of flurbiprofen: drug release and interactions. J Pharm Sci 2008; 97: 5306-5317.
80. Qaddoumi MG, etal. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res 2004; 21: 641-648.
81. Aksungur P, etal. Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake and kinetic studies. J Control Release 2011; 151: 286-294.
82. Qi H, etal. Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int J Pharm 2007; 337: 178-187.
83. Mansour M, etal. Ocular poloxamer-based ciprofloxacin hydrochloride in situ forming gels. Drug Dev Ind Pharm 2008; 4: 744-752.
84. Mayo L, etal. A novel poloxamers/hyaluronic acid in situ forming hydrogel for drug delivery: rheological, mucoadhesive and in vitro release properties. Eur J Pharm Biopharm 2008; 70: 199-206.
85. Shastri DH, etal. Studies on poloxamer based mucoadhesive insitu ophthalmic hydrogel of moxifloxacin HCL. Curr Drug Deliv 2010; 3: 77-86.
86. Hartikka J,. Physical characterization and in vivo evaluation of poloxamer-based DNA vaccine formulations. J Gene Med 2008; 10: 770-782.
87. Marchal-Heussler L, etal. Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm Res 1993; 10: 386-390.
88. Vandamme TF, Brobeck L,. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release 2005; 102: 23-38.
89. Yao WJ, etal. Effect of poly(amidoamine) dendrimers on corneal penetration of puerarin. Biol Pharm Bull 2010; 33: 1371-1377.
90. Wang WY, etal. Determination of puerarin in rabbit aqueous humor by liquid chromatography tandem mass spectrometry using microdialysis sampling after topical administration of puerarin PAMAM dendrimercomplex. J Pharm Biomed Anal 2011; 56: 825-829.
91. Whitehead KA, etal. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009; 8: 129-138.
92. Wood RW, etal. Ocular disposition of poly-hexyl-2-cyano(3-14C) acrylate nanoparticles in the albino rabbit. Int J Pharm 1985; 23: 175-183.
93. Sasaki H, etal. Retinal drug delivery using eyedrop preparations of poly-L-lysine-modified liposomes. Eur J Pharm Biopharm 2013; 83: 364-369.
94. Hiratani H, Alvarez-Lorenzo C,. Timolol uptake and release by imprinted soft contact lenses made of N,N-diethylacrylamide and methacrylic acid. J Control Release 2002; 83: 223-230.
95. Daull P, etal. A comparative study of a preservative-free latanoprost cationic emulsion (catioprost) and a BAK-preserved latanoprost solution in animal models. J Ocul Pharmacol Ther 2012; 28: 515-523.
96. Liang H, etal. Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Mol Vis 2008; 14: 204-216.
97. Furrer P, etal. Application of in vivo confocal microscopy to the objective evaluation of ocular irritation induced by surfactants. Int J Pharm 2000; 207: 89-98.
98. Rupenthal ID, etal. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: physicochemical characterisation and in vitro release. Int J Pharm 2011; 411: 69-77.
99. Liu Z, etal. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm 2006; 315: 12-17.
100. Liu Y, etal. In situ gelling gelrite/alginate formulations as vehicles for ophthalmic drug delivery. AAPS PharmSciTech 2010; 11: 610-620.
101. FDA. Inactive Ingredient Search for Approved Drug Products. 2013. http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm (accessed 1 July 2013).
102. Tadros T, etal. Formation and stability of nano-emulsions. Adv Colloid Interface Sci 2004; 108-109: 303-318.
103. Date AA, etal. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine 2010; 5: 1595-1616.
104. Solans C, etal. Nano-emulsions: formation, properties, and applications. In:, Mittal KL, Dinesh OS, eds. Adsorption and Aggregation of Surfactants in Solution. New York: Marcel Dekker, 2003: 525-554.
105. Anton N, etal. Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release 2008; 128: 185-199.
106. Morales D, etal. A study of the relation between bicontinuous microemulsions and oil/water nano-emulsion formation. Langmuir 2003; 19: 7196-7200.
107. Muchtar S, etal. A submicron emulsion as ocular vehicle for delta-S-tetrahydro-cannabinol: effect on intraocular pressure in rabbits. Ophthalmic Res 1992; 24: 142-149.
108. Teberikler L, etal. Selective extraction of phosphatidylcholine from lecithin by supercritical carbon dioxide/ethanol mixture. J Am Oil Chem Soc 2001; 78: 115-120.
109. Ohvo-Rekila H, etal. Cholesterol interactions with phospholipids in membranes. Prog Lipid Res 2002; 41: 66-97.
110. Naveh N,. A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits. Graefes Arch Clin Exp Ophthalmol 2000; 238: 334-338.
111. Calvo P, etal. Development of positively charged colloidal drug carriers: chitosan-coated polyester nanocapsules and submicron-emulsions. Colloid Polym Sci 1997; 275: 46-53.
112. Epstein SP, etal. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther 2009; 25: 113-119.
113. Ismail D, etal. A phase 2, randomized study evaluating the safety and efficacy of Catioprost® (unpreserved latanoprost 0.005% emulsion) compared to Travatan Z® in subjects with glaucoma and ocular surface disease. Acta Ophthalmol 2011; 89: 248s.
114. Maherani B, etal. Liposome: a review of manufacturing techniques and targeting strategies. Curr Nanosci 2011; 7: 436-452.
115. Ebrahim S, etal. Applications of liposomes in ophthalmology. Surv Ophthalmol 2005; 50: 167-182.
116. Kaur IP, etal. Vesicular systems in ocular drug delivery: an overview. Int J Pharm 2004; 269: 1-14.
117. Bochot A, Fattal E,. Liposomes for intravitreal drug delivery: a state of the art. J Control Release 2012; 161: 628-634.
118. Lee VHL, etal. Ocular drug bioavailability from topically applied liposomes. Surv Ophthalmol 1985; 29: 335-348.
119. Meisner D, Mezeib M,. Liposome ocular delivery systems. Adv Drug Deliv Rev 1995; 16: 75-93.
120. Kellaway IW, Farr SJ,. Liposomes as drug delivery systems to the lung. Adv Drug Deliv Rev 1990; 5: 49-16.
121. Huang SL,. Liposomes in ultrasonic drug and gene delivery. Adv Drug Deliv Rev 2008; 60: 1167-1176.
122. Egbaria K, Weiner N,. Liposomes as a topical drug delivery system. Adv Drug Deliv Rev 1990; 5: 287-300.
123. Sharma A, Sharma US,. Liposomes in drug delivery: progress and limitations. Int J Pharm 1997; 154: 123-140.
124. Hillery AM,. Supramolecular lipidic drug delivery systems: from laboratory to clinic A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B. Adv Drug Deliv Rev 1997; 24: 345-363.
125. Malam Y, etal. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009; 30: 592-599.
126. Allen TM, Cullis PR,. Liposomal drug delivery systems: from concept to clinical application. Adv Drug Deliv Rev 2012; 65: 36-48.
127. Kono K,. Thermosensitive polymer-modified liposomes. Adv Drug Deliv Rev 2001; 53: 307-319.
128. Cortesi R, Nastruzzi C,. Liposomes, micelles and microemulsions as new delivery systems for cytotoxic alkaloids. Pharm Sci Technolo Today 1999; 2: 288-298.
129. Shell JW,. Ophthalmic drug delivery systems. Surv Ophthalmol 1984; 29: 117-128.
130. Honda M, etal. Liposomes and nanotechnology in drug development: focus on ocular targets. Int J Nanomedicine 2013; 8: 495-503.
131. Smolin G, etal. Iodoxuridine-liposome therapy for herpes simplex keratitis. Am J Ophthalmol 1981; 91: 220-226.
132. El-Gazayerly ON, Hikal AH,. Preparation and evaluation of acetazolamide liposomes as an ocular delivery system. Int J Pharm 1997; 158: 121-127.
133. Morand K, etal. Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability. Int J Pharm 2007; 344: 150-153.
134. Law SL, etal. Acyclovir-containing liposomes for potential ocular delivery Corneal penetration and absorption. J Control Release 2000; 63: 135-140.
135. Craig JP, etal. Effect of a liposomal spray on the pre-ocular tear film. Cont Lens Anterior Eye 2012; 33: 83-87.
136. Matsuo T, etal. Gene transfer to the retina of rat by liposome eye drops. Biochem Biophys Res Commun 1996; 219: 947-950.
137. Frucht-Perry J, etal. Fibrin-enmeshed tobramycin liposomes: single application topical therapy of Pseudomonas keratitis. Cornea 1992; 11: 393-397.
138. Lajavardi L, etal. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis. J Control Release 2009; 139: 22-30.
139. Stratford RE, etal. Effects of topically applied liposomes on disposition of epinephrine and inulin in the albino rabbit eye. Int J Pharm 1983; 13: 263-272.
140. Pult H, etal. Effect of three different liposomal eye sprays on ocular comfort and tear film. Cont Lens Anterior Eye 2012; 35: 203-207.
141. Cortesi R, etal. Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity. Int J Pharm 2006; 317: 90-100.
142. Chetoni P, etal. Comparison of liposome-encapsulated acyclovir with acyclovir ointment: ocular pharmacokinectics in rabbits. J Ocul Pharmacol Ther 2004; 20: 169-177.
143. Lee VH, etal. Precorneal factors influencing the ocular distribution of topically applied liposomal inulin. Curr Eye Res 1984; 3: 585-591.
144. Schaeffer HE, etal. Lectin-mediated attachment of liposomes to cornea: influence on transcorneal drug flux. Invest Ophthalmol Vis Sci 1982; 23: 530-533.
145. McCalden TA, Levy M,. Retention of topical liposomal formulations on the cornea. Experientia 1990; 46: 713-715.
146. Schwendener RA, etal. The effects of charge and size on the interaction of unilamellar liposomes with macrophages. Biochim Biophys Acta 1984; 772: 93-101.
147. Schaeffer EH, Krohn DL,. Liposomes in topical drug delivery. Invest Ophthalmol Vis Sci 1982; 22: 220-227.
148. Zhang J, etal. Freeze-dried liposomes as potential carriers for ocular administration of cytochrome c against selenite cataract formation. J Pharm Pharmacol 2009; 61: 1171-1178.
149. Benita S, etal. Pilocarpine hydrochloride liposomes: characterization in vitro and preliminary evaluation in vivo in rabbit eye. J Microencapsul 1986; 1: 203-216.
150. Singh K, Mezei M,. Liposomal ophthalmic drug delivery system. I. Triamcinalone acetonide. Int J Pharm 1983; 16: 339-344.
151. Singh K, Mezei M,. Liposomal ophthalmic drug delivery system. II. Dihydrostreptomycin sulphate. Int J Pharm 1984; 19: 263-269.
152. He L, etal. Optimized flurbiprofen cationic liposomes. In situ gelling system of thermosensitive polymers for ocular delivery. J Appl Polym Sci 2012; 123: 3363-3374.
153. Hosny KM,. Ciprofloxacin as ocular liposomal hydrogel. AAPS PharmSciTech 2010; 11: 241-246.
154. Bochot A, etal. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci 2002; 43: 253-259.
155. Ito A, etal. Synthetic cationic amphiphiles for liposome-mediated DNA transfection. Biochem Int 1990; 22: 235-241.
156. Matsuura M, etal. Polycation liposome-mediated gene transfer in vivo. Biochim Biophys Acta 2003; 1612: 136-143.
157. Kawakami S, etal. In vivo gene transfection via intravitreal injection of cationic liposome/plasmid DNA complexes in rabbits. Int J Pharm 2004; 278: 255-262.
158. Bloquel C, etal. Non-viral ocular gene therapy: potential ocular terapeutic avenues. Adv Drug Deliv Rev 2006; 58: 1224-1242.
159. Sanders NN, etal. Wanted and unwanted properties of surface PEGylated nucleic acid nanoparticles in ocular gene transfer. J Control Release 2007; 122: 226-235.
160. Mehnert W, Mäder K,. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2012; 64: 83-101.
161. Puglia C, Bonina F,. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin Drug Deliv 2012; 9: 429-441.
162. Attama AA,. SLN, NLC, LDC: state of the art in drug and active delivery. Recent Pat Drug Deliv Formul 2011; 5: 178-187.
163. Müller RH, etal. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54: 131-155.
164. Mehnert W, Mäder K,. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165-196.
165. Iqbal MA, etal. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target 2012; 20: 813-830.
166. Tian BC, etal. Further investigation of nanostructured lipid carriers as an ocular delivery system: in vivo transcorneal mechanism and in vitro release study. Colloids Surf B Biointerfaces 2013; 102: 251-256.
167. Muller RH, etal. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002; 242: 121-128.
168. Cavalli R, etal. Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion-pair. Int J Pharm 1995; 117: 243-246.
169. Cavalli R, etal. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002; 238: 241-245.
170. Abul Kalam M, etal. Part II: enhancement of transcorneal delivery of gatifloxacin by solid lipid nanoparticles in comparison to commercial aqueous eye drops. J Biomed Mater Res A 2012; 101: 1828-1836.
171. Seyfoddin A, Al-Kassas R,. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm 2012; 39: 508-519.
172. Youshia J, etal. Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide. Int J Nanomedicine 2012; 7: 2483-2496.
173. Shen J, etal. Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement. Nanotechnology 2010; 21: 1-10.
174. Shen J, etal. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J Control Release 2009; 137: 217-223.
175. Shen J, etal. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution. Int J Pharm 2010; 402: 248-253.
176. Basaran E, etal. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul 2010; 27: 37-47.
177. Desai SD, Blanchard J,. Evaluation of pluronic F127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model. J Pharm Sci 1998; 87: 1190-1195.
178. Nanjwade BK, etal. Formulation and evaluation of micro hydrogel of Moxifloxacin hydrochloride. Eur J Drug Metab Pharmacokinet 2012; 37: 117-123.
179. Anumolu SS, etal. Design and evaluation of novel fast forming pilocarpine-loaded ocular hydrogels for sustained pharmacological response. J Control Release 2009; 137: 152-159.
180. Ma WD, etal. Pluronic F127-g-poly(acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system. Int J Pharm 2008; 350: 247-256.
181. Wang X, etal. Synthesis of biodegradable amphiphilic thermo-responsive multiblock polycarbonate and its self-aggregation behavior in aqueous solution. J Appl Polym Sci 2009; 112: 1425-1435.
182. El Kamel AH,. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int J Pharm 2002; 24: 47-55.
183. Asasutjarit R, etal. Optimization and evaluation of thermoresponsive diclofenac sodium ophthalmic in situ gels. Int J Pharm 2011; 411: 128-135.
184. Lin HR, Sung KC,. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Release 2000; 69: 379-388.
185. Sultana Y, etal. Evaluation of carbopol-methyl cellulose based sustained-release ocular delivery system for pefloxacin mesylate using rabbit eye model. Pharm Dev Technol 2006; 11: 313-319.
186. Wu C, etal. Preparation and evaluation of a Carbopol/HPMC-based in situ gelling ophthalmic system for puerarin. Yakugaku Zasshi 2007; 127: 183-191.
187. Wu H, etal. Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery. Int J Pharm 2011; 410: 31-40.
188. Waltman SR, Kaufman HE,. Use of hydrophilic contact lenses to increase ocular penetration of topical drugs. Invest Ophthalmol 1970; 9: 250-255.
189. Xu J, etal. Preparation and evaluation of a contact lens vehicle for puerarin delivery. J Biomater Sci Polym Ed 2010; 21: 271-288.
190. Peng CC, Chauhan AJ,. Extended cyclosporine delivery by silicone-hydrogel contact lenses. J Control Release 2011; 154: 267-274.
191. Gupta H, Aqil M,. Contact lenses in ocular therapeutics. Drug Discov Today 2012; 17: 522-527.
192. Gulsen D, Chauhan A,. Ophthalmic drug delivery through contact lenses. Invest Ophthalmol Vis Sci 2004; 45: 2342-2347.
193. Gulsen D, Chauhan A,. Dispersion of microemulsion drops in HEMA hydrogel: a potential ophthalmic drug delivery vehicle. Int J Pharm 2005; 292: 95-117.
194. Gulsen D, etal. Dispersion of DMPC liposomes in contact lenses for ophthalmic drug delivery. Curr Eye Res 2005; 30: 1071-1080.
195. Kapoor Y, Chauhan A,. Ophthalmic delivery of Cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels. Int J Pharm 2008; 361: 222-229.
196. Danion A, etal. Antibacterial activity of contact lenses bearing surface-immobilized layers of intact liposomes loaded with levofloxacin. J Pharm Sci 2007; 96: 2350-2363.
197. Garhwal R, etal. Sustained ocular delivery of ciprofloxacin using nanospheres and conventional contact lens materials. Invest Ophthalmol Vis Sci 2012; 53: 1341-1352.
198. Ribeiro A, etal. Bioinspired imprinted PHEMA-hydrogels for ocular delivery of carbonic anhydrase inhibitor drugs. Biomacromolecules 2011; 12: 701-709.
199. Hiratani H, etal. Ocular release of timolol from molecularly imprinted soft contact lenses. Biomaterials 2005; 26: 1293-1298.
200. Alvarez-Lorenzo C, etal. Imprinted soft contact lenses as norfloxacin delivery systems. J Control Release 2006; 113: 236-244.
201. Tieppo A,. In vitro controlled release of an anti-inflammatory from daily disposable therapeutic contact lenses under physiological ocular tear flow. Eur J Pharm Biopharm 2012; 81: 170-177.
202. Bergmann NM, Peppas NA,. Molecularly imprinted polymers with specific recognition for macromolecules and proteins. Prog Polym Sci 2008; 33: 271-288.
203. Kryscio DR, Peppas NA,. Mimicking biological delivery through feedback-controlled, recognitive drug release systems based on molecular imprinting methods. AIChE J 2009; 55: 1311-1324.
204. Tieppo A, etal. Sustained in vivo release from imprinted therapeutic contact lenses. J Control Release 2012; 157: 391-397.
205. Sahoo SK, etal. Nanotechnology in ocular drug delivery. Drug Discov Today 2008; 13: 144-151.
206. Kompella UB, etal. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci 2003; 44: 1192-1201.
207. Kompella UB, etal. Luteinizing hormone- releasing hormone agonist and transferri functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model. Mol Vis 2006; 12: 1185-1198.
208. Jwala J, etal. Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir. J Ocul Pharmacol Ther 2011; 27: 163-172.
209. Nagarwal RC, etal. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release 2009; 136: 2-13.
210. Bucolo C, etal. Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene. J Pharm Pharmacol 2004; 56: 841-846.
211. Pignatello R, etal. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 2002; 16: 53-61.
212. Rafie F, etal. In vivo evaluation of novel nanoparticles containing dexamethasone for ocular drug delivery on rabbit eye. Curr Eye Res 2010; 35: 1081-1089.
213. Kassem MA, etal. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 2007; 340: 126-133.
214. Lang JC,. Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev 1995; 16: 39-43.
215. Ali Y, Lehmussaari K,. Industrial perspective in ocular drug delivery. Adv Drug Deliv Rev 2006; 58: 1258-1268.
216. Musumeci T, etal. Polymeric nanoparticles augment the ocular hypotensive
217. Giannavola C, etal. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res 2003; 20: 584-590.
218. Esfand R, Tomalia DA,. Poly (amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 2001; 6: 427-436.
219. Mintzer MA, Grinstaff MW,. Biomedical applications of dendrimers: a tutorial. Chem Soc Rev 2011; 40: 173-190.
220. Kaminskas LM, etal. Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. Nanomedicine (Lond) 2011; 6: 1063-1084.
221. Liu M, Fréchet JM,. Designing dendrimers for drug delivery. Pharm Sci Technolo Today 1999; 2: 393-401.
222. Kurtoglu YE, etal. Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery. Biomaterials 2009; 30: 2112-2121.
223. Navath RS, etal. Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels. Bioconjug Chem 2008; 19: 2446-2455.
224. Antoni P, etal. Bifunctional dendrimers: from robust synthesis and accelerated one-pot postfunctionalization strategy to potential applications. Angew Chem Int Ed Engl 2009; 48: 2126-2130.
225. Kolhe P, etal. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm 2003; 259: 143-160.
226. Khandare J, etal. Synthesis, cellular transport, and activity of polyamidoamine dendrimer-methylprednisolone conjugates. Bioconjug Chem 2005; 16: 330-337.
227. Tomalia DA, etal. A new class of polymers: starburst dendritic macromolecules. Polym J 1985; 17: 117-132.
228. Malik N, etal. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 2000; 65: 133-148.
229. Zhou J, etal. PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun (Camb) 2006; 14: 2362-2364.
230. Bielinska A, etal. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res 1996; 24: 2176-2182.
231. Marano RJ, etal. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp Eye Res 2004; 79: 525-535.
232. Marano RJ, etal. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 2005; 12: 1544-1550.
233. Parekh HS, etal. Synthesis of a library of polycationic lipid core dendrimers and their evaluation in the delivery of an oligonucleotide with hVEGF inhibition. Bioorg Med Chem 2006; 14: 4775-4780.
234. Lopez RF, etal. Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Adv Drug Deliv Rev 2004; 56: 77-94.
235. Dutet J, Delgado-Charro MB,. In vivo transungual iontophoresis: effect of DC current application on ionic transport and on transonychial water loss. J Control Release 2009; 140: 117-125.
236. Gratieri T, etal. Excised porcine cornea integrity evaluation in an in vitro model of iontophoretic ocular research. Ophthalmic Res 2010; 43: 208-216.
237. Hao J, etal. Electrically assisted delivery of macromolecules into the corneal epithelium. Exp Eye Res 2009; 89: 934-941.
238. Marro D, etal. Contributions of electromigration and electroosmosis to iontophoretic drug delivery. Pharm Res 2001; 18: 1701-1708.
239. Von Sallmann L, Meyer K,. Penetration of penicillin into the eye. Arch Ophthalmol 1944; 31: 1-7.
240. Von Sallmann L,. Penicillin and sulfadiazine in the treatment of experimental intraocular infections with Staphylococcu aureus and Clostridium welchii. Arch Ophthalmol 1944; 31: 54-61.
241. Hughes L, Maurice DM,. A fresh look at iontophoresis. Arch Ophthalmol 1984; 102: 1825-1829.
242. Frucht-Pery J,. Iontophoresis-gentamicin delivery into the rabbit cornea, using a hydrogel delivery probe. Exp Eye Res 2004; 78: 745-749.
243. Eljarrat-Binstock E, etal. Transcorneal and transscleral iontophoresis of dexamethasone phosphate using drug loaded hydrogel. J Control Release 2005; 106: 386-390.
244. Lam T, etal. Transscleral iontophoresis of dexamethasone. Arch Ophthalmol 1989; 107: 1368-1371.
245. Behar-Cohen FF, etal. Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats. Exp Eye Res 1997; 65: 533-545.
246. Behar-Cohen FF, etal. Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels. Exp Eye Res 2002; 74: 51-59.
247. Eljarrat-Binstock E, etal. Methylprednisolone delivery to the back of the eye using hydrogel iontophoresis. J Ocul Pharmacol Ther 2008; 24: 344-350.
248. Molokhia SA, etal. Transscleral iontophoretic and intravitreal delivery of a macromolecule: study of ocular distribution in vivo and postmortem with MRI. Exp Eye Res 2009; 88: 418-425.
249. Li SK, etal. Effective electrophoretic mobilities and charges of anti-VEGF proteins determined by capillary zone electrophoresis. J Pharm Biomed Anal 2011; 55: 603-607.
250. Li SK, etal. Magnetic resonance imaging study of current and ion delivery into the eye during transscleral and transcorneal iontophoresis. Invest Ophthalmol Vis Sci 2004; 45: 1224-1231.
251. Parkinson TM, etal. Tolerance of ocular iontophoresis in healthy volunteers. J Ocul Pharmacol Ther 2003; 19: 145-151.
252. Bejjani RA, etal. Electrically assisted ocular gene therapy. Surv Ophthalmol 2007; 52: 196-208.
253. Asahara T, etal. Induction of gene into the rabbit eye by iontophoresis: preliminary report. Jpn J Ophthalmol 2001; 45: 31-39.
254. Voigt M, etal. Down-regulation of NOSII gene expression by iontophoresis of anti-senseoligonucleotide in endotoxin-induced uveitis. Biochem Biophys Res Commun 2002; 295: 336-341.
255. Berdugo M, etal. Delivery of antisense oligonucleotide to the cornea by iontophoresis. Antisense Nucleic Acid Drug Dev 2003; 13: 107-114.
256. Eljarrat-Binstock E, etal. Charged nanoparticles delivery to the eye using hydrogel iontophoresis. J Control Release 2008; 126: 156-561.
257. Chopra P, etal. Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera. J Control Release 2012; 160: 96-104.
258. Aciont. Visulex® System. 2008. http://www.aciont.com/technologies/ visulex. (accessed 21 June 2013).
259. Patane MA, etal. Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial. Clin Ophthalmol 2011; 5: 633-643.
260. Cohen AE, etal. Study investigators. evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating noninfectious anterior uveitis. Ophthalmology 2012; 119: 66-73.
261. Mitragotri S, etal. Transdermal drug delivery using low-frequency sonophoresis. Pharm Res 1996; 13: 411-420.
262. Lopez RF, etal. Enhancing the transdermal delivery of rigid nanoparticles using the simultaneous application of ultrasound and sodium lauryl sulfate. Biomaterials 2011; 32: 933-941.
263. Polat BE, etal. Transport pathways and enhancement mechanisms within localized and non-localized transport regions in skin treated with low-frequency sonophoresis and sodium lauryl sulfate. J Pharm Sci 2011; 100: 512-529.
264. Schoellhammer CM, etal. Rapid skin permeabilization by the simultaneous application of dual-frequency, high-intensity ultrasound. J Control Release 2012; 163: 154-160.
265. Zderic V, etal. Ocular drug delivery using 20-kHz ultrasound. Ultrasound Med Biol 2002; 28: 823-829.
266. Zderic V, etal. Ultrasound-Enhanced transcorneal drug delivery. Cornea 2004; 23: 804-811.
267. Zderic V, etal. Drug delivery into the eye with the use of ultrasound. J Ultrasound Med 2004; 23: 1349-1359.
268. Cheung ACY, etal. Ultrasound-enhanced intrascleral delivery of protein. Int J Pharm 2010; 401: 16-24.
269. Polat BE, etal. Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends. J Control Release 2011; 152: 330-348.
270. Tsok RM,. Phonophoresis in various diseases of the anterior segment of the eye. Oftalmol Zh 1979; 34: 73-76.
271. Egorov EA, etal. Results of intraocular pharmaco-physical therapy in inflammatory diseases of the cornea. Vestn Oftalmol 1995; 111: 31-34.
272. Marmur RK, etal. Current state and perspectives of further development of phonophoresis of drugs in ophthalmology. Oftalmol Zh 1979; 34: 68-73.
273. Lakimenko SA, Chalanova RI,. Phonophoresis of the proteolytic enzymes lekozim or kollalizin in the combined therapy of eye burns. Oftalmol Zh 1990; 6: 321-324.
274. Lakimento SA, etal. The use of lekozim phonophoresis for the treatment of eye burns. Oftalmol Zh 1989; 8: 492-497.
275. Gvarishvili EP, Dushin NV,. Effect of superphonoelectrophoresis on chorioretinal dystrophy. Vestn Oftalmol 1999; 115: 19-21.
276. Ueda H, etal. Acoustic cavitation as an enhancing mechanism of low-frequency sonophoresis for transdermal drug delivery. Biol Pharm Bull 2009; 32: 916-920.
277. Mullin L, etal. Nanoparticle delivery enhancement with acoustically activated microbubbles. IEEE Trans Ultrason Ferroelectr Freq Control 2013; 60: 65-77.
278. Kowalczuk L, etal. In vivo gene transfer into the ocular ciliary muscle mediated by ultrasound and microbubbles. Ultrasound Med Biol 2011; 37: 1814-1827.
279. Lee NG, etal. Sonoporation enhances chemotherapeutic efficacy in retinoblastoma cells in vitro. Invest Ophthalmol Vis Sci 2011; 52: 3868-3873.
280. Sanoda S, etal. Gene transfer to corneal epithelium and keratocytes mediated by ultrasound with microbubbles. Invest Ophthalmol Vis Sci 2006; 47: 558-564.
281. Sanoda S, etal. Ultrasound-mediated gene transfer into rat retina using micro-bubbles. Invest Ophthalmol Vis Sci 2005; 46: E-Abstract 5194.
282. Sanoda S, etal. Selective gene transfer to the retina using intravitreal ultrasound irradiation. J Ophthalmol 2012; 2012: 1-5.
283. Wirtz R,. Die Ionentherapie in der Augenheilkunde. Klin Mbl Augenheilk 1908; 46: 543. Nível Superior